8-K: Stereotaxis Reports 9% Revenue Increase in First Quarter 2025, Driven by Recurring Revenue Growth

Stereotaxis announced a 9% increase in revenue for Q1 2025, driven by a 29% rise in recurring revenue, and highlighted key commercial and innovation milestones.

Summary

• Stereotaxis reported its financial results for the first quarter ended March 31, 2025.
• Revenue for the first quarter of 2025 totaled $7.5 million, a 9% increase compared to $6.9 million in the prior year first quarter.
• System revenue was $2.0 million, compared to $2.6 million in the prior year first quarter, reflecting revenue recognition on the installation of a Genesis system.
• Recurring revenue was $5.5 million, growing 29% compared to $4.3 million in the prior year first quarter, predominantly reflecting contributions of Map-iT catheter revenue.
• Gross margin for the first quarter was 54% of revenue, with recurring revenue gross margin at 68% and system gross margin at 15%.
• Operating expenses in the first quarter were $10.0 million, including $3.2 million of non-cash charges.
• Adjusted operating expenses were $6.8 million, compared to $6.1 million in the prior year first quarter.
• Operating loss and net loss in the first quarter of 2025 were ($5.9) million and ($5.8) million, respectively.
• Adjusted operating loss and adjusted net loss for the quarter were ($2.7) million and ($2.6) million, respectively.
• Negative free cash flow for the first quarter was ($1.8) million, compared to ($2.3) million in the previous year.
• As of March 31, 2025, Stereotaxis had cash and cash equivalents of $10.7 million and no debt.
• The company reiterates its expectation of double-digit revenue growth for the full year 2025.
• System revenue is expected to be $2-3 million per quarter, and recurring revenue is expected to scale to $7 million in the fourth quarter.
• The company anticipates reduced cash use in 2025 compared to 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the revenue growth, strong recurring revenue, and expectations for future growth; however, the operating and net losses temper the overall outlook.

Positives

• Revenue increased by 9% year-over-year to $7.5 million in Q1 2025.
• Recurring revenue saw substantial growth of 29%, reaching $5.5 million.
• Stereotaxis maintains a strong cash position with $10.7 million and no debt.
• The company expects double-digit revenue growth for the full year 2025.
• Reduced cash use is anticipated in 2025 compared to 2024.
• Successful demonstrations of GenesisX at major global conferences indicate potential for future adoption.
• An additional Genesis order was received in the first quarter.

Negatives

• System revenue decreased to $2.0 million from $2.6 million in the prior year first quarter.
• The company experienced an operating loss of ($5.9) million and a net loss of ($5.8) million in Q1 2025.
• Adjusted operating loss and adjusted net loss also increased compared to the previous year.
• Gross margins are impacted by acquisition-related accounting and fixed overhead allocation.
• Operating expenses increased due to additional expenses from the operations of Access Point Technologies.

Risks

• The company's future performance is subject to risks, uncertainties, and other important factors that could cause actual results to differ materially.
• The company's ability to manage expenses at sustainable levels is a risk factor.
• Acceptance of the company's products in the marketplace is a risk factor.
• The timing of regulatory approvals could impact future performance.
• The company's dependence upon third-party vendors poses a risk.
• The company's purchase orders and other commitments are subject to contingencies that are outside of the company's control and may be revised, modified, delayed, or canceled.

Future Outlook

Stereotaxis expects double-digit revenue growth for the full year 2025, with system revenue of $2-3 million per quarter and recurring revenue scaling to $7 million in the fourth quarter; the company also anticipates reduced cash use in 2025 compared to 2024 and expects its balance sheet to allow it to advance its transformative product ecosystem to market, fund its commercialization, and profitably grow.

Management Comments

• David Fischel, Chairman and CEO, stated that the company has started the year with solid execution on key commercial and innovation efforts.
• David Fischel noted that this is a milestone rich year in which the company is beginning to demonstrate the tangible reality and commercial impact of its comprehensive innovation strategy.
• David Fischel believes that the milestones will increasingly contribute to commercial results as the company progresses through the year and set it up for breakout growth as it looks towards 2026.

Industry Context

Stereotaxis is positioning itself as a leader in surgical robotics for minimally invasive endovascular intervention, competing with other companies in the medical robotics and electrophysiology (EP) space; the company's focus on innovation, particularly with the Genesis and GenesisX systems, aims to provide a competitive edge in the market.

Comparison to Industry Standards

• Comparing Stereotaxis's 9% revenue growth to other medical device companies in the robotic surgery sector, companies like Intuitive Surgical often see higher growth rates, but Stereotaxis is in a niche market.
• The recurring revenue growth of 29% is a positive sign, as it indicates increasing adoption of Stereotaxis's disposable products, similar to how companies like Medtronic generate consistent revenue from their medical devices.
• The gross margin of 54% is lower than some established medical device companies, which often have gross margins above 60%, but this is attributed to acquisition-related accounting and low system production levels.
• The operating and net losses are a concern, but the company's focus on reducing cash use and achieving profitability in the future aligns with the goals of other growth-stage medical technology companies.

Stakeholder Impact

• Shareholders can expect potential future growth and value creation from the company's innovative products and strategic initiatives.
• Employees may benefit from the company's growth and expansion, leading to potential career opportunities.
• Customers (physicians and hospitals) can expect access to advanced robotic systems for minimally invasive endovascular intervention.
• Suppliers may benefit from increased demand for components and materials as the company's production scales up.

Next Steps

• Advance multiple development and regulatory efforts in parallel, with six active regulatory reviews ongoing and preparations for additional near-term regulatory submissions.
• Demonstrate the tangible reality of the company's overall strategic transformation into a company with an easily adopted robot that can navigate a proprietary set of catheters in EP and broadly across endovascular procedures.
• Continue commercialization of GenesisX in Europe.
• Await regulatory availability of GenesisX in the United States and install the first clinical system this summer.
• Host a conference call and webcast on May 12, 2025, at 4:30 p.m. Eastern Time.

Key Dates

Keywords

Stereotaxis, surgical robotics, endovascular intervention, financial results, revenue, Genesis, GenesisX, recurring revenue, Map-iT catheter, regulatory approvals